Collagen Cross Linking, or CXL is an outpatient procedure to help strengthen the middle of the cornea, the front clear window of the eye. Some corneal disease , like keratoconus ,can weaken the middle layer of the cornea, the stroma, and distort the cornea, making it shaped more like an irregular cone. This distorts light as light travels through the cornea, causing blurred vision.
Cross-linking is a minimally invasive outpatient procedure for the treatment of progressive keratoconus. iLink FDA-approved cross-linking combines the use of prescription eye drops, Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and ultra-violet A (UVA) light from the KXL® system to create new collagen cross-links and leads to the stiffening of the cornea. The goal of the procedure is to stiffen the cornea to slow or prevent further progression of the condition (keratoconus, or other corneal degenerative disease)and preserve your vision.